Skip to main content
. 2021 Feb 11;7(3):395–402. doi: 10.1001/jamaoncol.2020.7456

Figure 2. Comparison of Detected Clinically Significant Cancers by Each Screening Test According to Magnetic Resonance Imaging (MRI) and Ultrasonography (US) Threshold.

Figure 2.

A, Clinically significant cancer is defined as a Gleason score of 3+4 or higher (International Society of Urological Pathology score ≥2). Positive test results are defined as a prostate-specific antigen (PSA) level of 3 ng/mL or higher, an MRI score of 3 to 5, and a US score of 3 to 5. The PSA levels for the 8 men with MRI scores of 3 to 5 and a PSA level less than 3 ng/mL (to convert to micrograms per liter, multiply by 1) are provided in eTable 3 in the Supplement. B, Clinically significant cancer is defined as a Gleason score of 3+4 or higher (International Society of Urological Pathology score ≥2). TB indicates targeted biopsy; SB, systematic biopsy.